This week there was a lot of press about Abbott getting approval for their CGMS, the Libre Flash System (see item #5). The best part about this approval is the hope that there will be be more competition among the manufacturers, lower prices and increased third party coverage. This would be good based on the information we have …

Intensive control of blood pressure, glucose, and lipids benefits patients with type 2 diabetes, the long-awaited, large Japan Diabetes Optimal Integrated Treatment Study for 3 Major Risk Factors of Cardiovascular Diseases (J-DOIT3).

The results of the REMOVAL study were presented at the 2017 European Association for the Study of Diabetes (EASD) in Lisbon

Children and teenagers with type 1 diabetes are more likely to have eating disorders.

The investigational sodium/glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin (Merck), being developed to improve glycemic control in adults with type 2 diabetes, met the primary outcomes in two yearlong phase 3 trials, VERTIS SU and VERTIS SITA2.

First Continuous Glucose Monitor that doesn’t require routine finger pricks.

One of your patients is a 3-state regional salesman who has a fairly unpredictable work schedule. When he gets hungry while on the road, he tends to eat at the first restaurant he sees. For the past 3 months, he has managed his type 2 diabetes with metformin, glipizide, and glargine. Despite this regimen, his current A1C is 7.8%. You are in agreement that he needs to add a bolus insulin dose to his regimen. Which type of insulin would be the most appropriate choice? 1. Rapid-acting insulin analogues 2. Premixed insulin 3. Long-acting insulin analogues 4. Intermediate-acting insulin Follow the link to see the correct answer.

Which new drug do you prefer for a second-line therapy for a patient with type 2 patient diabetes? 1) GLP-1 Agonist 2) SGLT-2 Inhibitor 3) Long-acting insulin 4) TZD 5) Other Follow the link to share your response.

Global healthcare company Novo Nordisk, renewed its partnership with Team Novo Nordisk for an additional two years, extending the company’s commitment to the world’s first all-diabetes professional cycling team to a total of seven years.

Over the past year, we have been following Team Novo Nordisk, the professional cycling team, as they travel the world and remind all of us that diabetes is not a disease that you cannot overcome. You can imagine that the cost of sponsoring a UCI team is very high. As …